Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
Stocks mentioned in the article
ChangeLast1st jan.
BIOCON LTD 2.14% 651.5 End-of-day quote.18.35%
BRISTOL-MYERS SQUIBB COMPANY 1.34% 51.58 Delayed Quote.-16.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
04/23BRISTOL MYERS SQUIBB : Announces Worldwide Collaboration with Janssen to Develop..
AQ
04/23Bristol-Myers Squibb Company
AQ
04/23BRISTOL-MYERS SQUIBB COMPANY : - In CheckMate -141, Opdivo Demonstrated Sustaine..
AQ
04/23BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Approves Opdivo + Yervo..
AQ
04/21JOHNSON & JOHNSON : J&J, BMS Team Up on Cardiovascular Therapies
AQ
04/20JOHNSON & JOHNSON : Janssen Announces Worldwide Development and Commercializatio..
AQ
04/19BRISTOL MYERS SQUIBB : Study Findings on Antifungals Are Outlined in Reports fro..
AQ
04/19BRISTOL MYERS SQUIBB : and Harvard Announce New Fibrosis Research Collaboration
AQ
04/19BRISTOL MYERS SQUIBB : Data on Therapeutics Reported by Researchers at Bristol-M..
AQ
04/19BRISTOL MYERS SQUIBB : Myers announces phase 3 CheckMate -141 trial of Opdivo sh..
AQ
More news
News from SeekingAlpha
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/24Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerg.. 
04/23How To Retire At 65 With Only Half A Million 
04/22THE NO BS PLAN REPORT, WEEK 10 : Where The Reliable Falter 
04/22ROUNDS REPORT : Solid Biosciences Is Making A Comeback While Improving FDA Polic.. 
Financials ($)
Sales 2018 21 786 M
EBIT 2018 5 625 M
Net income 2018 4 991 M
Finance 2018 244 M
Yield 2018 3,15%
P/E ratio 2018 17,55
P/E ratio 2019 14,88
EV / Sales 2018 3,81x
EV / Sales 2019 3,48x
Capitalization 83 223 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 61,4 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-16.50%83 223
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571